
Tenaya Therapeutics Investor Relations Material
Latest events

Study Update
Tenaya Therapeutics

Q1 2025
7 May, 2025

Q4 2024
10 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Tenaya Therapeutics Inc
Access all reports
Tenaya Therapeutics Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for heart disease. The company's approach involves multiple therapeutic modalities, including gene therapy, cellular regeneration, and precision medicine, to address both rare genetic and prevalent forms of cardiovascular disease. Tenaya's research aims to target the underlying causes of heart disease, offering potential treatments for conditions that currently have limited therapeutic options. The company is headquartered in South San Francisco, California, and its shares are listed on the Nasdaq.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
TNYA
Country
🇺🇸 United States